Involvement of β-glucan receptors on the antitumor activity of β-glucans

This review examines receptors that may mediate the antitumor effects reported for beta-1,3-glucans. It covers established receptors such as Dectin-1 and complement receptor 3 together with additional proposed recognition pathways, and discusses how receptor signaling could affect innate and adaptive immune responses. The authors also consider the rationale for combining beta-glucans with immune-checkpoint treatment. The article is a mechanistic synthesis of prior work, not a clinical trial, so it supports biological hypotheses but does not by itself show that a beta-glucan treatment improves cancer outcomes in patients.